Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XRAY VISION
2023-508528-36-00Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Xevinapant + radiotherapy with Placebo + radiotherapy (2 arms). Primary endpoint: Disease-free survival. Started Feb 2024; status: completed.
02
Drugs
xevinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-508528-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508528-36-00.